A recent study based on a test involving a cocktail of probe drugs (including midazolam) for CYP3A enzymes revealed an approximately 38% decline of the mean metabolic activity of CYP3A enzymes in patients with type 2 diabetes mellitus in comparison with controls [382]. The gene discussed is CYP3A4; the disease is diabetes mellitus.